Nasdaq4d
Teva Pharmaceuticals and Alvotech Announce U.S. Launch of SELARSDI™ Biosimilar for Multiple Indications
In February 2025, Teva Pharmaceuticals and Alvotech announced ... the potential risk for shedding from the household contact and transmission to patient. Non-live vaccinations received during ...
Nasdaq4d
Teva Pharmaceuticals and Alvotech Announce U.S. Launch of SELARSDI™ Biosimilar for Autoimmune Diseases
This marks the second biosimilar released in the U.S. by the strategic partnership between Teva Pharmaceuticals ... from the household contact and transmission to patient. Non-live vaccinations ...
manilatimes4d
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...
TMDX DEADLINE NOTICE: BFA Law Alerts TransMedics Group, Inc. Investors that Lost Money to Contact the Firm by the April 15 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 25, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX ...
Morningstar4d
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals ... for shedding from the household contact and transmission to patient. Non-live vaccinations ...
Le Lézard4d
Teva and Alvotech Announce SELARSDItm (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...
Morningstar4d
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
Please click here for full Prescribing Information for SELARSDI. Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global pharmaceutical leader, one that operates ...
TMDX DEADLINE: TransMedics Group, Inc. Investors are Alerted to Contact BFA Law before Imminent April 15 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 23, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX ...
DelveInsight Business Research, LLP: Global Transmucosal Drugs Market to Reach ~USD 28 Billion by 2032 | DelveInsight
The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...